CorMedix Reports Strong 2025 Results But Warns of Significant DefenCath Reimbursement Decline in H2 2026
summarizeSummary
CorMedix Inc. announced preliminary strong financial results for Q4 and full-year 2025, but provided cautious 2026 and 2027 revenue guidance due to an anticipated significant decline in DefenCath reimbursement and net pricing in the second half of 2026.
check_boxKey Events
-
Preliminary 2025 Financials Exceed Guidance
CorMedix reported preliminary Q4 2025 net revenue of approximately $127 million and full-year 2025 net revenue of $310 million, surpassing previous guidance.
-
Significant DefenCath Reimbursement Decline Expected
The company anticipates a substantial reduction in DefenCath's net pricing in Q3 and Q4 2026 due to a transition to a lower post-TDAPA Add-On Adjustment, creating a material headwind.
-
Cautious 2026 and 2027 DefenCath Revenue Guidance
FY 2026 revenue guidance is $300 million to $320 million, with DefenCath sales of $150 million to $170 million heavily weighted to H1. FY 2027 DefenCath sales are estimated lower at $100 million to $140 million, despite an assumed higher net selling price relative to H2 2026.
-
CEO Assumes Chairman Role; New CCO Appointed
Joseph Todisco, CEO, will also serve as Chairman of the Board, and Mike Seckler was appointed EVP & Chief Commercial Officer, strengthening the leadership team.
auto_awesomeAnalysis
The company's preliminary Q4 and full-year 2025 financial results exceeded prior guidance, demonstrating strong performance. However, the forward-looking guidance for 2026 and 2027 is significantly impacted by an expected substantial reduction in DefenCath's net pricing starting in Q3 2026 due to changes in post-TDAPA Add-On Adjustment methodology. This creates a material headwind for a key product, leading to a heavily H1-weighted 2026 DefenCath revenue and a lower overall 2027 DefenCath sales estimate. Investors should monitor the actual impact of these reimbursement changes and the company's ability to mitigate the pricing pressure through utilization growth or potential legislative changes. The appointment of a new Chief Commercial Officer and the CEO's expanded role as Chairman aim to strengthen leadership for future growth, but the immediate focus will be on navigating the reimbursement challenges.
At the time of this filing, CRMD was trading at $10.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $880.1M. The 52-week trading range was $5.60 to $17.43. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.